Compared consolidated income statements
| € millions | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net sales | Net sales202341,182.5 | Net sales202238,260.6 | Net sales202132,287.6 |
| Cost of sales | Cost of sales 2023-10,767.0 |
Cost of sales 2022-10,577.4 |
Cost of sales 2021-8,433.3 |
| Gross profit | Gross profit202330,415.5 | Gross profit202227,683.3 | Gross profit202123,854.3 |
| Research & Innovation expenses | Research & Innovation expenses 2023-1,288.9 |
Research & Innovation expenses 2022-1,138.6 |
Research & Innovation expenses 2021-1,028.7 |
| Advertising and promotion expenses | Advertising and promotion expenses 2023-13,356.6 |
Advertising and promotion expenses 2022-12,059.0 |
Advertising and promotion expenses 2021-10,591.0 |
| Selling, general and administrative expenses | Selling, general and administrative expenses 2023-7,626.7 |
Selling, general and administrative expenses 2022-7,028.8 |
Selling, general and administrative expenses 2021-6,074.2 |
| Operating profit | Operating profit20238,143.3 | Operating profit20227,456.9 | Operating profit20216,160.3 |
| Other income and expenses | Other income and expenses 2023-449.9 |
Other income and expenses 2022-241.5 |
Other income and expenses 2021-432.0 |
| Operational profit | Operational profit20237,693.4 | Operational profit20227,215.4 | Operational profit20215,728.3 |
| Finance costs on gross debt | Finance costs on gross debt 2023-226.7 |
Finance costs on gross debt 2022-70.4 |
Finance costs on gross debt 2021-38.0 |
| Finance income on cash and cash equivalents | Finance income on cash and cash equivalents 2023162.1 |
Finance income on cash and cash equivalents 202269.8 |
Finance income on cash and cash equivalents 202118.5 |
| Finance costs, net | Finance costs, net2023-64.6 | Finance costs, net2022-0.6 | Finance costs, net2021-19.4 |
| Other financial income and expenses | Other financial income and expenses 2023-48.8 |
Other financial income and expenses 2022-72.3 |
Other financial income and expenses 2021-40.2 |
| Sanofi dividends | Sanofi dividends 2023420.9 |
Sanofi dividends 2022468.2 |
Sanofi dividends 2021378.3 |
| Profit before tax and associates | Profit before tax and associates20238,001.0 | Profit before tax and associates20227,610.6 | Profit before tax and associates20216,046.9 |
| Income tax | Income tax 2023-1,810.6 |
Income tax 2022-1,899.4 |
Income tax 2021-1,445.4 |
| Share of profit in associates | Share of profit in associates 20230.2 |
Share of profit in associates 20221.4 |
Share of profit in associates 20210.6 |
| Net profit | Net profit20236,190.5 | Net profit20225,712.6 | Net profit20214,602.2 |
| Attributable to: | Attributable to: 2023
|
Attributable to: 2022
|
Attributable to: 2021
|
| owners of the company | owners of the company 20236,184.0 |
owners of the company 20225,7066 |
owners of the company 20214,597.1 |
| non-controlling interests | non-controlling interests 20236.5 |
non-controlling interests 20226.0 |
non-controlling interests 20215.1 |
| Earnings per share attributable to owners of the company (euros) | Earnings per share attributable to owners of the company (euros)202311.55 |
Earnings per share attributable to owners of the company (euros)202210.65 |
Earnings per share attributable to owners of the company (euros)20218.24 |
| Diluted earnings per share attributable to owners of the company (euros) | Diluted earnings per share attributable to owners of the company (euros)202311.52 |
Diluted earnings per share attributable to owners of the company (euros)202210.61 |
Diluted earnings per share attributable to owners of the company (euros)20218.21 |
| Earnings per share attributable to owners of the company, excluding non-recurring items (euros) | Earnings per share attributable to owners of the company, excluding non-recurring items (euros)202312.11 |
Earnings per share attributable to owners of the company, excluding non-recurring items (euros)202211.30 |
Earnings per share attributable to owners of the company, excluding non-recurring items (euros)20218.86 |
| Diluted earnings per share attributable to owners of the company, excluding non‑recurring items (euros) | Diluted earnings per share attributable to owners of the company, excluding non‑recurring items (euros)202312.08 |
Diluted earnings per share attributable to owners of the company, excluding non‑recurring items (euros)202211.26 |
Diluted earnings per share attributable to owners of the company, excluding non‑recurring items (euros)20218.82 |
Sources and application of funds
This graph shows the sources and application of funds.
Sources
- Net profit attributable to owners of the company: 6,190.5
- Amortisation and provisions: 1,715.0
- Capital gains or losses on disposals of assets, changes in deferred taxes and other: 94.0
Applications
- Investments in tangible and intangible assets: 1,488.7
- Operating flow: 6,115.9
- Change in working capital requirement: 394.9
Gross cash flow: 7,999.5